Back to New York Presbyterian Hospital (Columbia Campus) Internal Medicine
Samuel Amaka
Resident · New York Presbyterian Hospital
Credentials: ·
History
Research
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Nature Medicine · 2024 · 50 citations
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
Blood · 2022 · 37 citations
Cell chemical biology · 2023 · 13 citations
- DW
3 papers
- CT
2 papers
- ND
2 papers
- RX
2 papers · 2 as a resident
1 paper · 1 as a resident
- AM
1 paper
1 paper
- AK
1 paper
